Skip to main content

Advertisement

SpringerLink
Log in

Direct medical cost of nephropathy in patients with type 2 diabetes

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Although it is known in the literature that the medical cost due to the complications of diabetes mellitus (DM) is high, data about the effect of diabetic kidney disease (DKD) on medical cost are limited.

Aims

The aim of this study is to investigate the cost of hospitalized patients with nephropathy due to type 2 DM, the parameters closely related to this cost and the effect of diabetic nephropathy stage on medical hospitalization costs.

Methods

The study group consisted of 141 patients with DKD, and the control group consisted of 111 patients with DM without chronic complications in this retrospective study. The demographic characteristics, duration of diabetes and HbA1c values of the patients were recorded at the time of their first hospitalization, medical hospitalization costs, and the length of stay in hospital were recorded for a year from the date of hospitalization. The total medical hospitalization costs of the patients were divided into two groups as cost of medications and supplies and service cost. Patients with DKD were compared according to their dialysis status and nephropathy stages.

Results

While the average cost of a patient with DKD was 603 (283–1267) United States Dollars (USD), the average cost of a DM patient without complications was 222 (141–292) USD (p < 0.05). It was observed that the patients with DKD had higher medical hospitalization costs and length of stay in hospital compared to patients with diabetes without complications. In addition, it was observed that the medical hospitalization costs and the length of stay in hospital were significantly higher in patients undergoing dialysis than patients who did not undergo dialysis (p < 0.05 for each). An independent relation was found between average cost and duration of diabetes in patients with DKD (p < 0.05). No relation was found between diabetic nephropathy stage and medical hospitalization costs (p > 0.05 for each).

Conclusion

The estimated cost of treatment of DKD is higher than patients with uncomplicated diabetes. If preventive measures are not taken for DKD, it will continue to be a heavy economic burden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843

    Article  Google Scholar 

  2. Williams R, Karuranga S, Malanda B et al (2020) Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 162:108072

    Article  Google Scholar 

  3. Keskek SÖ, Kırım S, Yanmaz N et al (2014) Direct medical cost of type 1 and type 2 diabetes in Turkey. Int J Diabetes Dev Ctries 34:77–81

    Article  Google Scholar 

  4. Keskek SO, Kirim S, Yanmaz N (2014) Estimated costs of the treatment of diabetic foot ulcers in a tertiary hospital in Turkey. Pak J Med Sci 30(5):968–971

    PubMed  PubMed Central  Google Scholar 

  5. Menzin J, Korn JR, Cohen J et al (2010) Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. JMCP 16(4):264–275

    Article  Google Scholar 

  6. Slabaugh SL, Curtis BH, Clore G et al (2015) Factors associated with increased healthcare costs in medicare advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US. J Med Econ 18(2):106–112

    Article  Google Scholar 

  7. Morsanutto A, Berto P, Lopatriello S et al (2006) Major complications have a impact on total annual medical cost of diabetes results of a database analysis. JDCJOURNAL 20:163–169

    Google Scholar 

  8. Pagano E, Bo S, Petrinco M et al (2009) Factors affecting hospitalization costs of in type 2 diabetic patients. JDCJOURNAL 23:1–6

    Google Scholar 

  9. Henriksson F, Agardh CD, Berne C et al (2000) Direct medical cost for patients with type 2 diabetes in Sweden. J Intern Med 248:387–396

    Article  CAS  Google Scholar 

  10. Chan BSW, Tsang MW, Lee VWY et al (2007) Cost of type 2 diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther 45(8):455–468

    Article  CAS  Google Scholar 

  11. Önsüz MF, Topuzoğlu A (2018) İstanbul İlinde Üç Hastanede Ayaktan İzlenen Tip II Diyabetik Hastalarda Glisemik Kontrolün Maliyet Etkinliğinin Değerlendirilmesi. Türk Dünyası Uygulama ve Araştırma Merkezi Halk Sağlığı Dergisi 3(2):1–14

    Google Scholar 

  12. Öcal EE, Önsüz MF (2018) Diyabet Hastalığının Ekonomik Yükü. Türk Dünyası Uygulama ve Araştırma Merkezi Halk Sağlığı Dergisi 3(1):24–31

    Google Scholar 

  13. Satman I, Ömer B, Tütüncü Y et al (2013) TURDEP—II Çalışma Grubu. Eur J Epidemiol 28(2):169–180

    Article  Google Scholar 

  14. Rosenzweig JL (2008) Diyabet ve Sağlık Hizmeti Sistemi Ekonomik ve Sosyal Maliyetler. In: Kahn CR, Weir GC, King GL et al (eds) Joslin’s Diabetes mellitus 1. Medikal Yayıncılık Ltd Şti, Baskı, pp 777–792

    Google Scholar 

  15. The United States Renal Data System (USRDS) annual data report (2018): epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

  16. Shilpasree AS, Patil VS, Revanasiddappa M et al (2021) Renal Dysfunction in Prediabetes: Confirmed by Glomerular Hyperfiltration and Albuminuria. J Lab Physicians 13(3):257–262

  17. Li R, Bilik D, Brown MB et al (2013) Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 19(5):421–430

    PubMed  PubMed Central  Google Scholar 

  18. Schirr-Bonnans S, Costa N, Derumeaux-Burel H et al (2017) Cost of diabetic eye, renal and foot complications: a methodological review. Eur J Health Econ 18(3):293–312

    Article  Google Scholar 

  19. Gordois A, Scuffham P, Makas A et al (2004) The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 18(1):18–26

    Article  Google Scholar 

  20. Davis WA, Knuiman MW, Hendrie D et al (2005) Determinants of diabetes attributable non–blood glucose—lowering medication costs in type 2 diabetes the Fremantle Diabetes Study. Diabetes Care 28:329–336

    Article  Google Scholar 

  21. Lee HA, Fung KW, Msc BF (2003) Analyzing hospital length of stay, Mean or median regression? Med Care 41(5):681–686

    PubMed  Google Scholar 

  22. Zhou Z, Chaudhari P, Yang H et al (2017) Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study. Diabetes Ther 8(3):555–571

    Article  Google Scholar 

  23. Vupputuri S, Kimes TM, Calloway MO et al (2014) The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications 28(1):10–16

    Article  Google Scholar 

Download references

Funding

We have not funding source for this manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Ministry of Health, Adana City Training and Research Hospital, Adana, Turkey

    Erdinç Gülümsek & Şakir Özgür Keşkek

Authors
  1. Erdinç Gülümsek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Şakir Özgür Keşkek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Şakir Özgür Keşkek.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gülümsek, E., Keşkek, Ş.Ö. Direct medical cost of nephropathy in patients with type 2 diabetes. Int Urol Nephrol 54, 1383–1389 (2022). https://doi.org/10.1007/s11255-021-03012-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-021-03012-4

Keywords

Search

Navigation